Cargando…
Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives
Although benzodiazepines have been used for 6 decades, many questions remain unanswered by research. The lived experiences of those adversely affected long term can provide insights into how these agents might be more thoughtfully prescribed. Here, perspectives of one such experience encompassing be...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056465/ https://www.ncbi.nlm.nih.gov/pubmed/35239167 http://dx.doi.org/10.1007/s12325-022-02055-y |
_version_ | 1784697668952391680 |
---|---|
author | Silvernail, Carrie M. Wright, Steven L. |
author_facet | Silvernail, Carrie M. Wright, Steven L. |
author_sort | Silvernail, Carrie M. |
collection | PubMed |
description | Although benzodiazepines have been used for 6 decades, many questions remain unanswered by research. The lived experiences of those adversely affected long term can provide insights into how these agents might be more thoughtfully prescribed. Here, perspectives of one such experience encompassing benzodiazepine initiation, ongoing use with adverse consequences and difficult discontinuation are presented through the eyes of an affected individual and a clinician. This experience highlights the importance of limited initiation and duration of use (2–4 weeks) as well as a supported, slow tapering process led by patients. Because researched evidence about deprescribing benzodiazepines is insufficient and because individual experiences vary so widely, it is the patient’s expertise—that of her or his lived experience—that should assume a primary role in determining the course and pace of discontinuing these medications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02055-y. |
format | Online Article Text |
id | pubmed-9056465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-90564652022-05-07 Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives Silvernail, Carrie M. Wright, Steven L. Adv Ther Commentary Although benzodiazepines have been used for 6 decades, many questions remain unanswered by research. The lived experiences of those adversely affected long term can provide insights into how these agents might be more thoughtfully prescribed. Here, perspectives of one such experience encompassing benzodiazepine initiation, ongoing use with adverse consequences and difficult discontinuation are presented through the eyes of an affected individual and a clinician. This experience highlights the importance of limited initiation and duration of use (2–4 weeks) as well as a supported, slow tapering process led by patients. Because researched evidence about deprescribing benzodiazepines is insufficient and because individual experiences vary so widely, it is the patient’s expertise—that of her or his lived experience—that should assume a primary role in determining the course and pace of discontinuing these medications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02055-y. Springer Healthcare 2022-03-03 2022 /pmc/articles/PMC9056465/ /pubmed/35239167 http://dx.doi.org/10.1007/s12325-022-02055-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Commentary Silvernail, Carrie M. Wright, Steven L. Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives |
title | Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives |
title_full | Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives |
title_fullStr | Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives |
title_full_unstemmed | Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives |
title_short | Surviving Benzodiazepines: A Patient’s and Clinician’s Perspectives |
title_sort | surviving benzodiazepines: a patient’s and clinician’s perspectives |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056465/ https://www.ncbi.nlm.nih.gov/pubmed/35239167 http://dx.doi.org/10.1007/s12325-022-02055-y |
work_keys_str_mv | AT silvernailcarriem survivingbenzodiazepinesapatientsandcliniciansperspectives AT wrightstevenl survivingbenzodiazepinesapatientsandcliniciansperspectives |